top of page

This Canadian Nursery Is Exporting New Cannabis Strains To German Cannabis Producer Demecan

Big League Genetics, a Canadian cannabis nursery and partner of 3WIN Corp, announced on Wednesday that it has completed the export of cannabis genetics to DEMECAN, a licensed German cannabis producer.

The move comes shortly after Germany legalized recreational cannabis. As of April 1, adults over 18 can legally possess up to 25 grams of dried cannabis and cultivate up to three marijuana plants at home.

Beginning July 1, adults can also join not-for-profit social clubs where they can buy up to 25 grams of cannabis, with a cap of 50 grams per month. That cap is 30 grams for members under 21 years old.

Marijuana legalization in Germany will be one of many hot topics at the upcoming Benzinga Cannabis Capital Conference which returns to Florida on April 16 and 17.

Dave Auger, commissioner of Big League Genetics, praised the deal with DEMECAN.

“This is an exciting collaboration at an exciting time,” Auger said. “Big League has been supplying DEMECAN with medical cannabis for the past year and a half and we are elated to continue our meaningful work together in genetics just as Germany is taking groundbreaking steps in cannabis legalization.”

Dr. Adrian Fischer, managing director and co-founder of DEMECAN – the only German vertically integrated medicinal cannabis company – shared Auger's enthusiasm.

“We are thrilled to announce the beginning of our partnership with Big League, marking a significant milestone in our journey,” Fischer said. “This collaboration aims to enrich the German and European markets with top-tier cannabis genetics. Using our tissue culture lab, we are committed to setting new standards for quality and innovation.”

Benzinga recently spoke to Dr. Fischer's colleague, Dr. Constantin von der Groeben, a managing director of Demecan about cannabis legalization in Germany.

He said the reform ushers in opportunities for innovation, research and development.

"The recent legislative reforms in Germany mark a transformative chapter not only for Demecan but for the entire medical cannabis sector within the country," Dr. von der Groeben explained. "A crucial aspect of these reforms is the reclassification of cannabis from a narcotic to a prescription (Rx) drug,” he said, predicting that the market will show substantial growth in the first few years."

For Demecan, the new policy reform is important as it allows it to fully utilize its production capabilities, enables it to directly interface with pharmacies, choose and cultivate strains based on market demand and medical efficacy and independently negotiate price, explained von Der Groeben.


bottom of page